Pancreatic Cancer Adjuvant Therapy: ASCO Tumor Boards

This course is available as part of the 2017 ASCO Tumor Boards bundle.

This is a case-based activity that includes discussion of a 65-year-old male, with no chronic medical problems but had a 40-pack year history of cigarette smoking.  He presented with painless jaundice. In the past three months he has lost 20 pounds. His father, who was also a smoker, died from pancreatic cancer at the age of 73.

At the end of this course, learners should be able to:

  1. Describe the criteria for resectability for pancreatic adenocarcinoma
  2. Describe the evolution of adjuvant therapy clinical trials over the last three decades
  3. Acknowledge the different practice patterns regarding the utilization of adjuvant radiation therapy
  4. Review the data supporting the use of capecitabine and gemcitabine in the adjuvant treatment of ductal adenocarcinoma of the pancreas from the ESPAC-4 trial
  5. Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care

 IMPORTANT NOTE: This course expires on January 18, 2020. Participants must complete all necessary course components by this date.